Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Стенокардия Принцметала. Новый взгляд на патогенез и подходы к лечению

Полный текст:

Аннотация

В статье представлены современные сведения об этиологии и патогенезе вазоспастической стенокардии с указанием наиболее вероятных генетических факторов заболевания, влияния нейрогуморальных факторов. Особое внимание уделено роли фермента Rho-киназы в механизмах коронароспазма; с патогенетических позиций освещены новые медикаментозные подходы к терапии стенокардии Принцметала, а также возможности ее хирургического лечения.

Об авторах

И. Г. Фомина
Московская медицинская академия им. И.М. Сеченова. Москва
Россия


В. В. Матвеев
Московская медицинская академия им. И.М. Сеченова. Москва
Россия


Н. А. Галанина
Московская медицинская академия им. И.М. Сеченова. Москва
Россия


Е. Л. Перская
Московская медицинская академия им. И.М. Сеченова. Москва
Россия


Список литературы

1. Prinzmetal M, Kennamar R, Merliss R, et al. Angina pectoris. A variant form of angina pectoris. Am J Med 1959; 27: 375-88.

2. Hillis LD, Braunwald E. Coronary artery spasm. N Engl J Med 1978; 229: 695-702.

3. Koyanagi S, Takeshita A, Nakamura N. Clinical characteristics of sudden cardiac death in patients with vasospastic angina. Jpn Circ J 1989; 53(12): 1541-5.

4. David PR, Waters DD, Scholl JM, et al. Percutaneous transluminal coronary angioplasty in patients with variant angina. Circulation 1982; 66: 695-702.

5. American College of Cardiology/American Heart Association Task Force on Practice Guidelines Committee on the management of patients with unstable angina. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. Catheter Cardiovasc Interv 2000; 51(4): 505-21.

6. Lanza GA, Pedrotti P, Pasceri V, et al. Autonomic changes associated with spontaneous coronary spasm in patients with variant angina. JACC 1996; 28(5): 1249-56.

7. Bauters С. Angina pectoris. Epidemiology, etiology, physiopathology, diagnosis, course, treatment. Rev Prat 1996; 46(20): 2471-7.

8. Yasue H, Omote S, Takizawa A, et al. Coronary arterial spasm in ischemic heart disease and its pathogenesis. Circ Res 1983; 52(Suppl I): 147-52.

9. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. JACC 1999; 33(6): 1442-52.

10. Sueda S, Suzuki J, Watanabe K, et al. Comparative results of coronary intervention in patients with variant angina versus those with non-variant angina. Jpn Heart J 2001; 42(6): 657-67.

11. Bory M, Pierron F, Panagides D, et al. Coronary artery spasm in patients with normal or near normal coronary arteries. Eur Heart J 1996; 17: 1015-21.

12. Delacretaz E, Kirshenbaum JM, Friedman PL. Prinzmetal’s angina. Circulation 2000; 101(11): E107-8.

13. Murase Y, Yamada Y, Hirashiki A, et al. Genetic risk and geneenvironment interaction in coronary artery spasm in Japanese men and women. Eur Heart J 2004; 25(11): 970-7.

14. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 2000; 64: 1-12.

15. Kaski JC, Crea F, Meran D, et al. Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina. Circulation 1986; 74: 1255-65.

16. Igawa A, Miwa K, Miyagi Y, et al. Comparison of frequency of magnesium deficiency in patients with vasospastic angina and fixed coronary artery disease. Am J Cardiol 1995; 75(10): 728- 31.

17. Hong MK, Park SW, Lee CW, et al. Intravascular ultrasound findings of negative arterial remodeling at sites of focal coronary spasm in patients with vasospastic angina. Am Heart J 2000; 140: 395-401.

18. Fujita H, Hiroshi Y, Mitsuhiro Y. Dipyridamole-induced reversible Thallium-201 defect in patients with vasospastic angina and nearly normal coronary arteries. Clin Cardiol 2000; 23: 24-30.

19. Teragawa H, Kato M, Kurokawa J, et al. Endothelial dysfunction is an independent factor responsible for vasospastic angina. Clin Sci 2001; 101: 707-13.

20. Miller D, Waters DD, Warnica W, et al. Is variant angina the coronary manifestation of a generalized vasospastic disorder? N Engl J Med 1981; 304(13): 763-6.

21. Teragawa H, Kato M, Yamagata T, et al. The preventive effect of magnesium on coronary spasm in patients with vasospastic angina. Chest 2000; 118: 1690-5.

22. Teragawa H, Ueda K, Matsuda K, et al. Relationship between endothelial function in the coronary and brachial arteries. Clin Cardiol 2005; 28(10): 460-6.

23. Bryan RM, You J, Golding EM, et al. Endothelium-derived hyperpolarizing factor: a cousin to nitric oxide and prostacyclin. Anesthesiology 2005; 102 (6): 1261-77.

24. Triggle CR, Hollenberg M, Anderson TJ, et al. The endothelium in health and disease – a target for therapeutic intervention. J Smooth Muscle Res 2003; 39(6): 249-67.

25. Poredos P. Endothelial dysfunction and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32(5-6): 274-7.

26. Nakayama M, Yasue H, Yoshimura M, et al. AT-786 C mutation in the 5’-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-70.

27. Luscher TF, Georg N. Is It All in the Genes? Nitric oxide synthase and coronary vasospasm. Circulation 1999; 99: 2855-7.

28. Kawano H, Motoyama T, Ohgushi M, et al. Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med 2001; 135: 977-80.

29. Chierchia S, Davies G, Berkenboom G, et al. Alpha-adrenergic receptors and coronary spasm: An elusive link. Circulation 1984; 69: 8-14.

30. Okumara K, Yasue H, Matsuyama K, et al. Diffuse disorder of coronary vasomotility in patients with coronary spastic angina: Hyperreactivity to the constrictor effects of acetylcholine and dilator effects of nitroglycerin. JACC 1996; 27: 45-52.

31. Bertrand ME, Lablanche JM, Tilmant PY, et al. Complete denervation of the heart (autotransplantation) for treatment of severe, refractory coronary spasm. Am J Cardiol 1981; 47: 1375-80.

32. Nademanee K, Intarachot V, Josephson MA, et al. Circadian variation in occurrence of transient overt and silent myocardial ischemia in chronic stable angina and comparison with Prinzmetal’s angina in men. Am J Cardiol 1987; 60: 494-8.

33. Somers VK, Dyken ME, Mark AL, et al. Sympathetic-nerve activity during sleep in normal subjects. N Engl J Med 1993; 328: 303-7.

34. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996; 15(9): 2208-16.

35. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273(5272): 245-8.

36. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105(13): 1545-7.

37. Niiro N, Nishimura J, Sakihara C, et al. Up-regulation of rho A and rho-kinase mRNAs in the rat myometrium during pregnancy. Biochem Biophys Res Commun 1997; 230(2): 356-9.

38. Greijer AE, van der Groep P, Kemming D, et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005; 206(3): 291-304.

39. Kawano H., Ogawa H. Endothelial function and coronary spastic angina. Intern Med 2005; 44(2): 91-9.

40. Lanza GA, De Candia E, Romagnoli E, et al. Increased platelet sodium–hydrogen exchanger activity in patients with variant angina. Heart 2003; 89: 935-6.

41. Esterbauer H, Dieber-Rotheneder M, Striegl G, et al. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 1991; 53(Suppl): 314S-21.

42. Miwa K, Miyagi Y, Igawa A, et al. Vitamin E deficiency in variant angina. Circulation 1996; 94: 14-8.

43. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87: 76-9.

44. Miwa K, Fujita M, Miyagi Y, et al. High-density lipoprotein cholesterol level and smoking modify the prognosis of patients with coronary vasospasm. Clin Cardiol 1995; 18(5): 267-72.

45. Козлов Ю.С., Кузнецов С.И., Морева Е.Ю., Бессонова О.А. Диагностика вазоспастической стенокардии: современные подходы. Воронежская областная клиническая больница. Кафедра терапии № 1 ФПК и ППС, 2004. 16 c.

46. Дупляков Д.В. Неинвазивная диагностика спазма коронарных артерий. Функц ультразвук диаг 2002; 1: 134-6.

47. Keller KB, Lemberg L. Prinzmetal’s angina. Am J Crit Care 2004; 13(4): 350-4.

48. Orford J. Coronary artery vasospasm. Emedicine files, 2004. http://www.emedicine.com/ med/topic447.htm.

49. Mohlenkamp S, Eggebrecht H, Ebralidze T, et al. Normal coronary angiography with myocardial bridging: a variant possibly relevant for ischemia. Herz 2005; 30(1): 37-47.

50. Gowda RM, Khan IA, Patlola RR, et al. Multivessel coronary spasm during coronary angiography: coronary vasospastic disease. Int J Cardiol 2003; 89(2-3): 301-2.

51. Auer J, Berent R, Weber T, et al. Angiographic results of “atypical” chest pain. Herz 2002; 27(8): 772-9.

52. Henpler FA. Provocative testing for coronary artery spasm: risk, method and rationale. Am J Cardiol 1980; 46: 335-7.

53. Okumara K, Yasue H, Matsuyama K, et al. Sensitivity and specifivity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. GACC 1988; 12: 883-8.

54. Conti CR. Coronary artery spasm: provocative testing. Clin Cardiol 1994; 17: 353.

55. Li CC, Tamai H, Xu YS. Ergometrine provocative test for diagnosing variant angina pectoris. Hunan Yi Ke Da Xue Xue Bao 2000; 25(1): 93-4.

56. Cheng T. Ergonovine maleate and beta-blockers for Prinzmetal’s angina. Circulation 2001; 103(6): E30.

57. Kugiyama K, Miyao Y, Sakamoto T, et al. Glutathione attenuates coronary constriction to acetylcholine in patients with coronary spastic angina. Am J Physiol Heart Circ Physiol 2001; 280: H264-71.

58. Hayashi Y, Ibe T, Kawato H, et al. Postpartum acute myocardial infarction induced by ergonovine administration. Intern Med 2003; 42(10): 983-6.

59. Sueda S, Kohno H, Fukuda H. Clinical and angiographical characteristics of acetylcholine- induced spasm: relationship to dose of intracoronary injection of acetylcholine. Coron Artery Dis 2002; 13(4): 231-6.

60. Kijima M. Treatment and prognosis of vasospastic angina. Nippon Rinsho 2003;61(Suppl 5): 159-66.

61. Rutizky B, Girotti AL, Rosenbaum MB. Efficacy of chronic amiodarone therapy in patients with variant angina pectoris and inhibition of ergonovine coronary constriction. Am Heart J 1982; 103: 38-43.

62. Frenneaux M, Kaski JC, Brown M, et al. Refractory variant angina relieved by guanethidine and clonidine. Am J Cardiol 1988; 62: 832-3.

63. Sueda S, Saeki H, Otani T. Limited efficacy of magnesium for the treatment of variant angina. J Cardiol 1999; 34(3): 139-47.

64. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105(13): 1545-7.

65. Waters DD, Miller DD, Szlachcic J, et al. Factors influencing the long-term prognosis of treated patients with variant angina. Circulation 1983; 68: 258-65.

66. Walling A, Waters D, Miller D, et al. Long term prognosis of patients with variant angina. Circulation 1987; 5: 990-7.

67. Costa J, Pereira MA, Correia A, et al. Sudden death and variant angina. Rev Port Cardiol 2002; 21(11): 1305-14.

68. Kaku B, Mizuno S, Ohsato K, et al. Plasma endothelin-1 elevation associated with alcohol-induced variant angina. Jpn Circ J 1999; 63(7): 554-8.

69. Kim HS, Lee MM, Oh BH, et al. Variant angina is not associated with angiotensin I converting enzyme gene polymorphism but rather with smoking. Coron Artery Dis 1999; 10(4): 227-33.

70. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21(17): 1406-32.

71. Serrador A, Roman JA, Duran JM, et al. Successful treatment of vasospastic angina with a coronary stent. J Invasive Cardiol 2000; 12(11): 586-8.

72. Cheng TO. Percutaneous coronary intervention for variant angina: balloon vs. stent. Catheter Cardiovasc Interv 2002; 56(1): 21.

73. Tanabe Y, Itoh E, Suzuki K, et al. Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. JACC 2002; 39(7): 1120-6.

74. Erne P, Jamshidi P, Juelke P, et al. Brachytherapy: potential therapy for refractory coronary spasm. JACC 2004; 44(7): 1415-9.


Для цитирования:


Фомина И.Г., Матвеев В.В., Галанина Н.А., Перская Е.Л. Стенокардия Принцметала. Новый взгляд на патогенез и подходы к лечению. Кардиоваскулярная терапия и профилактика. 2006;5(6):116-122.

For citation:


Fomina I.G., Matveev V.V., Galanina N.A., Perskaya E.L. Prinzmetal angina: new approaches to pathogenesis and treatment. Cardiovascular Therapy and Prevention. 2006;5(6):116-122. (In Russ.)

Просмотров: 801


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)